375 related articles for article (PubMed ID: 21376233)
21. Crystal Structure and Substrate Specificity of PTPN12.
Li H; Yang F; Liu C; Xiao P; Xu Y; Liang Z; Liu C; Wang H; Wang W; Zheng W; Zhang W; Ma X; He D; Song X; Cui F; Xu Z; Yi F; Sun JP; Yu X
Cell Rep; 2016 May; 15(6):1345-58. PubMed ID: 27134172
[TBL] [Abstract][Full Text] [Related]
22. Expression and clinical significance of
Jin Y; Wang TX; Li H; Guo P; Wang QQ
J Int Med Res; 2020 Dec; 48(12):300060520936041. PubMed ID: 33292053
[TBL] [Abstract][Full Text] [Related]
23. Protein tyrosine phosphatase nonreceptor type 12 suppresses the proliferation of renal cell carcinoma by inhibiting the activity of the PI3K/mTOR pathway.
Piao YR; Jin ZH
J BUON; 2015; 20(5):1258-66. PubMed ID: 26537073
[TBL] [Abstract][Full Text] [Related]
24. Structure and Molecular Dynamics Simulations of Protein Tyrosine Phosphatase Non-Receptor 12 Provide Insights into the Catalytic Mechanism of the Enzyme.
Dong H; Zonta F; Wang S; Song K; He X; He M; Nie Y; Li S
Int J Mol Sci; 2017 Dec; 19(1):. PubMed ID: 29278368
[TBL] [Abstract][Full Text] [Related]
25. CD99-Derived Agonist Ligands Inhibit Fibronectin-Induced Activation of β1 Integrin through the Protein Kinase A/SHP2/Extracellular Signal-Regulated Kinase/PTPN12/Focal Adhesion Kinase Signaling Pathway.
Lee KJ; Kim Y; Yoo YH; Kim MS; Lee SH; Kim CG; Park K; Jeoung D; Lee H; Ko IY; Hahn JH
Mol Cell Biol; 2017 Jul; 37(14):. PubMed ID: 28483911
[TBL] [Abstract][Full Text] [Related]
26. Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer.
Grob TJ; Heilenkötter U; Geist S; Paluchowski P; Wilke C; Jaenicke F; Quaas A; Wilczak W; Choschzick M; Sauter G; Lebeau A
Breast Cancer Res Treat; 2012 Jul; 134(2):561-7. PubMed ID: 22610646
[TBL] [Abstract][Full Text] [Related]
27. Tyrosine-protein phosphatase non-receptor type 12 expression is a good prognostic factor in resectable non-small cell lung cancer.
Cao X; Chen YZ; Luo RZ; Zhang L; Zhang SL; Zeng J; Jiang YC; Han YJ; Wen ZS
Oncotarget; 2015 May; 6(13):11704-13. PubMed ID: 25868976
[TBL] [Abstract][Full Text] [Related]
28. Expression, purification and characterization of a catalytic domain of human protein tyrosine phosphatase non-receptor 12 (PTPN12) in Escherichia coli with FKBP-type PPIase as a chaperon.
Sui Y; Fu X; Wang Y; Hu W; Zhang T; Liu W; Jiang L; Xing S; Fu X; Xu X
Protein Expr Purif; 2018 Feb; 142():45-52. PubMed ID: 28965803
[TBL] [Abstract][Full Text] [Related]
29. Post-transcriptional regulation of chemokine receptor CXCR4 by estrogen in HER2 overexpressing, estrogen receptor-positive breast cancer cells.
Sengupta S; Schiff R; Katzenellenbogen BS
Breast Cancer Res Treat; 2009 Sep; 117(2):243-51. PubMed ID: 18807177
[TBL] [Abstract][Full Text] [Related]
30. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met.
Mueller KL; Madden JM; Zoratti GL; Kuperwasser C; List K; Boerner JL
Breast Cancer Res; 2012 Jul; 14(4):R104. PubMed ID: 22788954
[TBL] [Abstract][Full Text] [Related]
31. Negative regulation of HER2 signaling by the PEST-type protein-tyrosine phosphatase BDP1.
Gensler M; Buschbeck M; Ullrich A
J Biol Chem; 2004 Mar; 279(13):12110-6. PubMed ID: 14660651
[TBL] [Abstract][Full Text] [Related]
32. PIM kinase isoform specific regulation of MIG6 expression and EGFR signaling in prostate cancer cells.
Siu A; Virtanen C; Jongstra J
Oncotarget; 2011 Dec; 2(12):1134-44. PubMed ID: 22193779
[TBL] [Abstract][Full Text] [Related]
33. Hepatitis B virus mutations, expression quantitative trait loci for PTPN12, and their interactions in hepatocellular carcinoma.
Song C; Liu Y; Xu L; Wen J; Jiang D; Chen J; Zhai X; Hu Z; Liu L; Liu J
Cancer Med; 2016 Jul; 5(7):1687-93. PubMed ID: 27075395
[TBL] [Abstract][Full Text] [Related]
34. Oncogenic EGFR Represses the TET1 DNA Demethylase to Induce Silencing of Tumor Suppressors in Cancer Cells.
Forloni M; Gupta R; Nagarajan A; Sun LS; Dong Y; Pirazzoli V; Toki M; Wurtz A; Melnick MA; Kobayashi S; Homer RJ; Rimm DL; Gettinger SJ; Politi K; Dogra SK; Wajapeyee N
Cell Rep; 2016 Jul; 16(2):457-471. PubMed ID: 27346347
[TBL] [Abstract][Full Text] [Related]
35. Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer.
He J; McLaughlin RP; van der Noord V; Foekens JA; Martens JWM; van Westen G; Zhang Y; van de Water B
Breast Cancer Res Treat; 2019 Nov; 178(2):263-274. PubMed ID: 31388935
[TBL] [Abstract][Full Text] [Related]
36. The antitumorigenic function of EGFR in metastatic breast cancer is regulated by expression of Mig6.
Wendt MK; Williams WK; Pascuzzi PE; Balanis NG; Schiemann BJ; Carlin CR; Schiemann WP
Neoplasia; 2015 Jan; 17(1):124-33. PubMed ID: 25622905
[TBL] [Abstract][Full Text] [Related]
37. Co-targeting EGFR and mTOR with gefitinib and everolimus in triple-negative breast cancer cells.
El Guerrab A; Bamdad M; Bignon YJ; Penault-Llorca F; Aubel C
Sci Rep; 2020 Apr; 10(1):6367. PubMed ID: 32286420
[TBL] [Abstract][Full Text] [Related]
38. Differential impact of EGFR-targeted therapies on hypoxia responses: implications for treatment sensitivity in triple-negative metastatic breast cancer.
El Guerrab A; Zegrour R; Nemlin CC; Vigier F; Cayre A; Penault-Llorca F; Rossignol F; Bignon YJ
PLoS One; 2011; 6(9):e25080. PubMed ID: 21966417
[TBL] [Abstract][Full Text] [Related]
39. α-TEA cooperates with chemotherapeutic agents to induce apoptosis of p53 mutant, triple-negative human breast cancer cells via activating p73.
Tiwary R; Yu W; Sanders BG; Kline K
Breast Cancer Res; 2011 Jan; 13(1):R1. PubMed ID: 21214929
[TBL] [Abstract][Full Text] [Related]
40. SHP2 acts both upstream and downstream of multiple receptor tyrosine kinases to promote basal-like and triple-negative breast cancer.
Matalkah F; Martin E; Zhao H; Agazie YM
Breast Cancer Res; 2016 Jan; 18(1):2. PubMed ID: 26728598
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
